{"nctId":"NCT03158311","briefTitle":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","startDateStruct":{"date":"2018-02-05","type":"ACTUAL"},"conditions":["Asthma"],"count":1426,"armGroups":[{"label":"QVM149 150/50/80 μg","type":"EXPERIMENTAL","interventionNames":["Drug: QVM149"]},{"label":"QVM149 150/50/160 μg","type":"EXPERIMENTAL","interventionNames":["Drug: QVM149"]},{"label":"Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmeterol/fluticasone plus tiotropium"]}],"interventions":[{"name":"QVM149","otherNames":[]},{"name":"Salmeterol/fluticasone plus tiotropium","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with a diagnosis of asthma for a period of at least 6 months prior to Visit 1 with current asthma severity ≥ step 4 (GINA 2017).\n* Patients who had used ICS/LABA combinations for asthma for at least 3 months and at stable medium or high dose of ICS/LABA for at least 1 month prior to Visit 1.\n* Patients were required to be symptomatic at screening despite treatment with medium or high stable doses of ICS/LABA as defined by ACQ-7 score ≥ 1.5 at visits 101 and 201 (randomization visit).\n* Patients with history of at least one severe asthma exacerbation which required medical care from a physician, emergency room visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1 and required systemic corticosteroid treatment for at least 3 days including physician guided self-management treatment with oral corticosteroids as part of written asthma action plan.\n* Pre-bronchodilator FEV1 of \\< 85 % of the predicted normal value for the patient after withholding bronchodilators prior to spirometry at both Visit 101 and Visit 201.\n* Patients who demonstrated an increase in FEV1 of ≥ 12% and 200 ml.\n\nExclusion Criteria:\n\n* Patients who had a smoking history of greater than 20 pack years.\n* Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).\n* Patients who had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening).\n* Patients treated with a LAMA for asthma within 3 months prior to Visit 1.\n* Patients who had a respiratory tract infection or clinical significant asthma worsening as defined by Investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 201.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score","description":"The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional funtion, and emotional stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.715","spread":"0.070"},{"groupId":"OG001","value":"0.827","spread":"0.069"},{"groupId":"OG002","value":"0.753","spread":"0.069"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1)","description":"FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is the mean of two FEV1 values measures taken 15 minutes (min) and 45 min prior to evening dose.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.246","spread":"0.020"},{"groupId":"OG001","value":"0.309","spread":"0.020"},{"groupId":"OG002","value":"0.243","spread":"0.020"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.251","spread":"0.020"},{"groupId":"OG001","value":"0.319","spread":"0.020"},{"groupId":"OG002","value":"0.253","spread":"0.020"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.248","spread":"0.021"},{"groupId":"OG001","value":"0.334","spread":"0.021"},{"groupId":"OG002","value":"0.238","spread":"0.021"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score","description":"The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.043","spread":"0.045"},{"groupId":"OG001","value":"-1.098","spread":"0.045"},{"groupId":"OG002","value":"-1.020","spread":"0.045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.080","spread":"0.046"},{"groupId":"OG001","value":"-1.172","spread":"0.045"},{"groupId":"OG002","value":"-1.048","spread":"0.046"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in AQLQ Total Score","description":"The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.690","spread":"0.069"},{"groupId":"OG001","value":"0.755","spread":"0.068"},{"groupId":"OG002","value":"0.673","spread":"0.069"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Decrease From Baseline ACQ-7 ≥ 0.5","description":"The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue medication use and 1 on airway calibre (FEV1 % predicted). All seven items are scored on a 7-point Likert scale, with 0 indicating total control and 6 indicating poor control. The questions are equally weighted and the total score is the mean of the seven items. Higher score indicates worst symptoms. The first 6 questions of the ACQ-7 were completed by the participant while the last question was completed by the study investigator using data from the Master Scope spirometer. A negative change from baseline indicates improvement in lung function. Decrease of ACQ-7 score of at least 0.5 from baseline was considered clinically meaningful.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"387","spread":null},{"groupId":"OG002","value":"375","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Change From Baseline AQLQ ≥ 0.5","description":"The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale, where 1=totally limited/problems all the time and 7= not at all limited/no problems. It consists of 4 domains: symptoms, activity limitation, emotional function and environmental stimuli. The overall score is calculated as the mean of 32 items. Higher AQLQ scores indicate better health-related quality of life. An improvement of 0.5 points in AQLQ score is considered to be the minimally clinically important difference in asthma.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"333","spread":null},{"groupId":"OG002","value":"299","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Forced Vital Capacity (FVC)","description":"FVC is the total volume of air exhaled during a expiratory maneuvre. It was assessed by performing a spirometry assessment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.216","spread":"0.021"},{"groupId":"OG001","value":"0.272","spread":"0.021"},{"groupId":"OG002","value":"0.219","spread":"0.021"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.221","spread":"0.021"},{"groupId":"OG001","value":"0.275","spread":"0.021"},{"groupId":"OG002","value":"0.217","spread":"0.021"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.214","spread":"0.022"},{"groupId":"OG001","value":"0.280","spread":"0.022"},{"groupId":"OG002","value":"0.186","spread":"0.022"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75)","description":"Forced expiratory flow during the mid (25 - 75%) portion of the FVC. It was assessed by performing spirometric assessment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.290","spread":"0.027"},{"groupId":"OG001","value":"0.332","spread":"0.027"},{"groupId":"OG002","value":"0.270","spread":"0.027"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.291","spread":"0.028"},{"groupId":"OG001","value":"0.355","spread":"0.027"},{"groupId":"OG002","value":"0.297","spread":"0.027"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.290","spread":"0.028"},{"groupId":"OG001","value":"0.375","spread":"0.028"},{"groupId":"OG002","value":"0.286","spread":"0.028"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":474},"commonTop":["Asthma","Nasopharyngitis","Bronchitis","Pharyngitis","Headache"]}}}